Journal of Contemporary Brachytherapy

Clinical outcomes after interstitial high-dose-rate brachytherapy vs. stereotactic body radiotherapy in hepatocellular carcinoma: A retrospective matched single-center analysis

Sebastian Teich 1
,
Anna-Maria Bühler 1
,
Sebastian Schäfer 1, 2
,
Philipp Geisler 1, 2
,
Saskia Spautz 1, 2
,
Isabell Prager 1, 3
,
Stefan Dietzsch 1, 3
,
Ilias Sachpazidis 4
,
Dimos Baltas 4
,
Christos Moustakis 1, 2
,
Nils H. Nicolay 1, 3
,
Franziska Nägler 1, 3
,
Kathrin Hering 1, 3

  1. Department of Radiotherapy, University Hospital Leipzig, Germany

  2. Division of Medical Physics, Department of Radiotherapy, University Hospital Leipzig, Germany

  3. Comprehensive Cancer Center Central Germany, Partner Site Leipzig, Germany

  4. Division of Medical Physics, Department of Radiation Oncology, Medical Center – University of Freiburg, Faculty of Medicine, Freiburg, Germany

J Contemp Brachytherapy 2026

DOI: https://doi.org/10.5114/jcb.2026.164138
Data publikacji online: 2026/08/24
Article file
Clinical outcomes after.pdf
  1. Bray F, Laversanne M, Sung H et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2024; 74: 229-263.
  2. Yang A, Ju W, Yuan X et al. Comparison between liver resection and liver transplantation on outcomes in patients with solitary hepatocellular carcinoma meeting UNOS criteria: a population-based study of the SEER database. Oncotarget 2017; 8: 97428-97438.
  3. Krenzien F, Schmelzle M, Struecker B et al. Liver transplantation and liver resection for cirrhotic patients with hepatocellular carcinoma: comparison of long-term survivals. J Gastrointest Surg 2018; 22: 840-848.
  4. Drefs M, Schoenberg MB, Börner N et al. Changes of long-term survival of resection and liver transplantation in hepatocellular carcinoma throughout the years: A meta-analysis. Eur J Surg Oncol 2024; 50: 107952.
  5. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin 2020; 70: 7-30.
  6. Li X, Xu Y, Ou Y et al. Optimizing treatment selection for early hepatocellular carcinoma based on tumor biology, liver function, and patient status. J Hepatocell Carcinoma 2025; 12: 777-790.
  7. Liu QJ, Zhang JC, Wang YF et al. Correlation of radiotherapy, targeted therapy, and immunotherapy with hepatocellular carcinoma recurrence. World J Gastrointest Oncol 2025; 17: 107815.
  8. Vogel A, Chan SL, Dawson LA et al. Hepatocellular carcinoma: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol 2025; 36: 491-506.
  9. Sapir E, Tao Y, Schipper MJ et al. Stereotactic body radiation therapy as an alternative to transarterial chemoembolization for hepatocellular carcinoma. Int J Radiat Oncol Biol Phys 2018; 100: 122-130.
  10. Bettinger D, Pinato DJ, Schultheiss M et al. Stereotactic body radiation therapy as an alternative treatment for patients with hepatocellular carcinoma compared to sorafenib: a propensity score analysis. Liver Cancer 2019; 8: 281-294.
  11. Lee J, Shin IS, Yoon WS et al. Comparisons between radiofrequency ablation and stereotactic body radiotherapy for liver malignancies: Meta-analyses and a systematic review. Radiother Oncol 2020; 145: 63-70.
  12. Walter F, Fuchs F, Gerum S et al. HDR brachytherapy and SBRT as bridging therapy to liver transplantation in HCC patients: a single-center experience. Front Oncol 2021; 11: 717792.
  13. Méndez Romero A, van der Holt B, Willemssen FEJA et al. Transarterial chemoembolization with drug-eluting beads versus stereotactic body radiation therapy for hepatocellular carcinoma: outcomes from a multicenter, randomized, phase 2 trial (the TRENDY Trial). Int J Radiat Oncol Biol Phys 2023; 117: 45-52.
  14. Jazmati D, Boda-Heggemann J, Blanck O et al. Therapieentscheidungen beim hepatozellulären Karzinom: Erkenntnisse aus der TRENDY-Studie. Strahlenther Onkol 2023; 199: 954-956.
  15. Auer TA, Anhamm M, Böning G et al. Effectiveness and safety of computed tomography-guided high-dose-rate brachytherapy in treating recurrent hepatocellular carcinoma not amenable to repeated resection or radiofrequency ablation. Eur J Surg Oncol 2024; 50: 108429.
  16. Mohnike K, Wieners G, Schwartz F et al. Computed tomography-guided high-dose-rate brachytherapy in hepatocellular carcinoma: safety, efficacy, and effect on survival. Int J Radiat Oncol Biol Phys 2010; 78: 172-179.
  17. Collettini F, Schnapauff D, Poellinger A et al. Hepatocellular carcinoma: computed-tomography-guided high-dose-rate brachytherapy (CT-HDRBT) ablation of large (5-7 cm) and very large (7 cm) tumours. Eur Radiol 2012; 22: 1101-1109.
  18. Collettini F, Schreiber N, Schnapauff D et al. CT-guided high-dose-rate brachytherapy of unresectable hepatocellular carcinoma. Strahlenther Onkol 2015; 191: 405-412.
  19. Schnapauff D, Collettini F, Hartwig K et al. CT-guided brachytherapy as salvage therapy for intrahepatic recurrence of HCC after surgical resection. Anticancer Res 2015; 35: 319-323.
  20. Denecke T, Stelter L, Schnapauff D et al. CT-guided interstitial brachytherapy of hepatocellular carcinoma before liver transplantation: an equivalent alternative to transarterial chemoembolization? Eur Radiol 2015; 25: 2608-2616.
  21. Mohnike K, Steffen IG, Seidensticker M et al. Radioablation by image-guided (HDR) brachytherapy and transarterial chemoembolization in hepatocellular carcinoma: a randomized phase II trial. Cardiovasc Intervent Radiol 2019; 42: 239-249.
  22. Hass P, Mohnike K, Kropf S et al. Comparative analysis between interstitial brachytherapy and stereotactic body irradiation for local ablation in liver malignancies. Brachytherapy 2019; 18: 823-828.
  23. Bilski M, Korab K, Stąpór-Fudzińska M et al. HDR brachytherapy versus robotic-based and linac-based stereotactic ablative body radiotherapy in the treatment of liver metastases – A dosimetric comparison study of three radioablative techniques. Clin Transl Radiat Oncol 2024; 48: 100815.
  24. Bilski M, Peszyńska-Piorun M, Konat-Bąska K et al. Radiotherapy as a metastasis directed therapy for liver oligometastases - comparative analysis between CT-guided interstitial HDR brachytherapy and two SBRT modalities performed on double-layer and single layer LINACs. Front Oncol 2024; 14: 1478872.
  25. Dejonckheere CS, Bilski M, Nour Y et al. A dosimetric comparison of different radiotherapy modalities for non-resected oligometastatic liver disease. Clin Transl Radiat Oncol 2025; 52: 100947.
  26. Geissler P, Spautz S, Hering K et al. Comparison of interstitial high-dose-rate brachytherapy and stereotactic radiotherapy in breath-hold technique for inoperable primary and secondary liver tumors. Phys Imaging Radiat Oncol 2025; 35: 100811.
  27. Brunner TB, Boda-Heggemann J, Bürgy D et al. Dose prescription for stereotactic body radiotherapy: general and organ-specific consensus statement from the DEGRO/DGMP Working Group Stereotactic Radiotherapy and Radiosurgery. Universität, Freiburg 2024.
  28. Corradini S, Nierer L, Rottler M et al. The GEC ESTRO Handbook of Brachytherapy. 2nd edition. Chapter 28. Primary and secondary liver malignancies. 2022.
  29. Elm EV, Altman DG, Egger M et al. Strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies. BMJ 2007; 335: 806-808.
  30. Rivard MJ, Coursey BM, DeWerd LA et al. Update of AAPM Task Group No. 43 Report: A revised AAPM protocol for brachytherapy dose calculations. Med Phys 2004; 31: 633-674.
  31. Lewis S, Barry A, Hawkins MA. Hypofractionation in hepatocellular carcinoma – the effect of fractionation size. Clin Oncol (R Coll Radiol) 2022; 34: e195-e209.
  32. National Cancer Institute. Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0. https://ctep.cancer.gov/protocoldevelopment/electronic_applications/ctc.htm (12 April 2025, date last accessed).
  33. Stuart EA. Matching methods for causal inference: A review and a look forward. Stat Sci 2010; 25: 1-21.
  34. Mansoorian S, Hering S, Hofmaier J et al. Comparative analysis of target volume coverage and liver exposure in high-dose-rate interstitial brachytherapy and in silico MR LINAC-based stereotactic body radiotherapy plans for colorectal liver metastases. Clin Transl Radiat Oncol 2026; 56: 101030.
  35. Walter F, Nierer L, Rottler M et al. Comparison of liver exposure in CT-guided high-dose rate (HDR) interstitial brachytherapy versus SBRT in hepatocellular carcinoma. Radiat Oncol 2021; 16: 86.
  36. Bilski M, Korab K, Orzechowska M et al. Comprehensive cohort study: computer tomography-guided high-dose rate brachytherapy as metastasis-directed therapy for liver metastases from colorectal cancer in repeat oligoprogression. Radiol Med 2025; 130: 694-705.
  37. Bae SH, Chun SJ, Chung JH et al. Stereotactic body radiation therapy for hepatocellular carcinoma: meta-analysis and international stereotactic radiosurgery society practice guidelines. Int J Radiat Oncol Biol Phys 2024; 118: 337-351.
  38. Sperduto W, Oyekunle T, Niedzwiecki D et al. Toxicity of ablative radiation therapy in the management of patients with Child-Pugh B/C liver function and unresectable hepatocellular carcinoma (HCC). Cancers (Basel) 2026; 18: 681.
  39. Khosla D, Gade VKV, Kapoor R et al. Stereotactic body radiation therapy in patients with unresectable hepatocellular carcinoma and portal vein tumor thrombosis. World J Hepatol 2025; 17: 110993.
  40. Sanuki N, Kimura T, Takeda A et al. Final results of a multicenter prospective study of stereotactic body radiation therapy for previously untreated solitary primary hepatocellular carcinoma (The STRSPH Study). Int J Radiat Oncol Biol Phys 2025; 121: 942-950.
  41. Mohnike K, Wolf S, Damm R et al. Radioablation of liver malignancies with interstitial high-dose-rate brachytherapy: Complications and risk factors. Strahlenther Onkol 2016; 192: 288-296.
  42. Mohnike K, Sauerland H, Seidensticker M et al. Haemorrhagic complications and symptomatic venous thromboembolism in interventional tumour ablations: the impact of peri-interventional thrombosis prophylaxis. Cardiovasc Intervent Radiol 2016; 39: 1716-1721.
Copyright: © 2026 Termedia Sp. z o. o. This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License (http://creativecommons.org/licenses/by-nc-sa/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
SUBMIT YOUR PAPER
Share
without publication fees
Indexed in
pubmed
Integrated with
integrated with publons
Editorial Policies
Sarajevo Declaration on Integrity and Visibility of Scholarly Publications